周二夜盘，脑再生科技（RGC）股价大涨11.76%，延续了日间交易的强劲涨势。该公司股价近期表现抢眼，主要受益于脑机接口概念的持续发酵和投资者对神经科学领域的热捧。
脑再生科技是一家专注于利用中医药治疗神经认知障碍的生物科技公司，主要研究注意力缺陷与多动障碍（ADHD）和自闭症谱系障碍（ASD）的治疗方法。近期，脑机接口概念股在全球市场集体爆发，成为推动脑再生科技股价上涨的重要因素。马斯克旗下的Neuralink公司估值已达90亿美元，并计划在2025年为20-30名患者植入脑机芯片，这一消息进一步激发了投资者对脑机接口技术前景的乐观预期。
值得注意的是，脑再生科技今年以来的股价表现极为亮眼，截至近期，其股价已累计上涨超过599倍，市值一度高达385亿美元。然而，如此巨大的涨幅也伴随着较高的波动性和风险。该公司目前仍未产生营收，且研发投入相对较低。投资者在关注该股投资机会的同时，也应当充分认识到其中蕴含的高风险，谨慎决策。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.